Jennifer Woyach, MD - Real-World Challenges and Solutions with BTKi in CLL: Therapeutic Insights for Community Practice

Go online to PeerView.com/DWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. First- and second-generation Bruton tyrosine kinase (BTK) inhibitors have transformed the standard of care in many different chronic lymphocytic leukemia (CLL) settings—from treatment-naïve to relapsed disease, as well as in high-risk settings—but are you prepared to fully integrate established and emerging BTKi options into clinical practice, including in the context of community-based care? Find out by viewing this activity, which highlights the clinical decision-making of an academic and a community specialist. Throughout, the panelists will use a series of real-world cases to demonstrate the practicalities of using modern BTKi therapy, provide guidance on the use of next-generation agents, and offer a strong grounding for updated AE management protocols that can ensure safe delivery of care. Upon completion of this activity, participants should be better able to: Summarize evidence from pivotal clinical trials and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations; Recommend personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Select individualized, sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Manage adverse events associated with the use of novel targeted approaches with BTK inhibitors in the CLL setting.